Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational pharmacokinetic study of doxorubicin and cyclophosphamide in patients with early breast cancer
2005-004126-56Phase 4Unknown
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Feb 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of doxorubicin, epirubicin, cyclophosphamide and fluorouracil in breast cancer, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Blood concentrations of doxorubicin, epirubicin, cyclophosphamide, fluorouracil and their metabolites, Correlation of pharmacokinetics with toxicity (white blood cell nadir count) and 1 more. Status: unknown.
02
Drugs
doxorubicinepirubicincyclophosphamidefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004126-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004126-56.